Alerta

NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND USES THEREOF

Resumen de: US2025241854A1

Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES

Resumen de: AU2025205348A1

Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome. Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.

MRNA ENCODING INFLUENZA VIRUS-LIKE PARTICLE

Resumen de: AU2023394992A1

The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.

PHARMACEUTICAL FORMULATIONS OF GENE DELIVERY VEHICLES

Resumen de: AU2024209247A1

41 P6105182WOThe invention relates to formulations comprising miRNA that have improved stability for the treatment of diseases including neurodegenerative diseases such as spinocerebellar ataxias type 3. 5

NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY

Resumen de: AU2024206838A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response. Compositions described herein include nanoparticles, optionally including an inorganic particle, capable of admixing with nucleic acids encoding proteins, antibodies, or immunomodulators. Methods of using the compositions as a therapeutic vaccine for the treatment of an infection or cancer are also provided.

METHOD FOR PURIFICATION OF LIPID NANOPARTICLES

Resumen de: AU2024223881A1

The present invention relates to methods for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid, comprising the steps of subjecting a solution containing said LNPs to a chromatographic medium with convective flow properties in the presence of at least one kosmotropic agent; and eluting LNPs from said chromatographic medium. The present invention further relates to respective uses of a chromatographic medium with convective flow properties for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid.

IONIZABLE LIPID, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREPARING LIPID NANOPARTICLE

Resumen de: US2025243151A1

An ionizable lipid having a structure represented by the following formula (I):wherein Y is independently selected from a group consisting of —NH—, —O—, —S—, and a single bond; X is independently selected from —NR1R2 or a nitrogen-containing heteroaryl group; L1 and L2 are each independently selected from a group consisting of a C1-C10 alkylene group, a C2-C10 alkenylene group,R1 and R2 are each independently selected from a group consisting of H, a substituted or unsubstituted C1-C10 hydrocarbyl group, a substituted or unsubstituted C1-C10 heterohydrocarbyl group, a substituted or unsubstituted C6-C20 aryl group, and a substituted or unsubstituted C1-C20 heteroaryl group; R3 is a C5-C30 alkyl group; R4 is a C5-C30 alkyl group; n is an integer selected from 1 to 10; and m and p are each independently an integer selected from 1 to 20.

NANOALUM PARTICLES CONTAINING A PEGYLATED LIPID SIZING AGENT

Resumen de: US2025241864A1

Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

DELIVERY OF THERAPEUTIC RECOMBINANT URICASE USING NANOPARTICLES

Resumen de: US2025241999A1

Systems for enhanced delivery of functional, recombinant soluble uricase enzymes with long serum residence, low immunogenicity and potential for modification have been developed. Compositions and methods of use thereof of nanoparticles including recombinant soluble uricase enzymes are provided for oral administration to a subject. The nanoparticle compositions include recombinant soluble uricase enzymes that are not PEGylated, and have a serum residence time of hours, days or weeks following oral administration. A reduced level of side effects of the formulation provides an effective and safe drug delivery platform for treating Tumor Lysis syndrome and Lesch-Nyhan disease, as well as hyperuricemia and associated diseases or disorders.

NANOLIPOSOME COMPOSITIONS AND METHODS OF TREATING STROKE

Resumen de: US2025241985A1

Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of stroke.

NOVEL SECRETORY SIGNAL PEPTIDES

Resumen de: AU2023347284A1

Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.

LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF

Resumen de: WO2024064800A2

Disclosed herein are lipid nanoparticles comprising plurality of lipids, a targeting moiety for an HIV-1 chemokine receptor, and a CRISPR nucleic acid complementary to an HIV-1 gene, pharmaceutical compositions and methods of use thereof.

LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS ENCODING THERAPEUTIC GENES AND USES IN MEDICAL METHODS

Resumen de: WO2024064206A1

This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.

POLYMER NANOPARTICLES OF METABOLITES AND USE THEREOF

Resumen de: EP4591856A1

The present disclosure relates to polymer nanoparticles of metabolites, a cell activity promotion method using same, and a cell activity promotion composition including same. In particular, the present disclosure relates to a method and a composition, for promoting, by the permeation of polymer nanoparticles of metabolites into cells, the activities of cells, for example, adhesion between cells or between tissues, hemostasis, wound healing promotion, hair root regeneration activity, and antibacterial activity.

LIPID NANOPARTICLE, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: EP4591859A1

The invention discloses a lipid nanoparticle and a preparation method and application thereof are provided. The lipid nanoparticle (LNP) includes a carrier and an encapsulated nucleic acid, the carrier includes an ionizable lipid, a helper phospholipid, a PEGylated lipid, cholesterol and its derivatives, and a retinoid compound; and the nucleic acid is one or more of mRNA, circRNA, siRNA, microRNA, antisense nucleic acid, and plasmid. The invention proves that the five-component LNP can activate the triple immune response of body fluid, cells and mucosa after intramuscular or subcutaneous administration, and has important application prospects in the field of infectious disease vaccines and mucosal-related tumor vaccines.

LIPID NANOPARTICLE FOR RADIATION THERAPY, MANUFACTURING METHOD, COMBINATION COMPOSITION, AND KIT

Resumen de: EP4591890A1

According to one arrangement, a radiotherapy lipid nanoparticle (10) includes a biodegradable lipid nanoparticle (11), and a radioactive material (12) as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.

LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO

Resumen de: MX2025003345A

Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least a cationic lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the LNP comprises at least one glycerol dialkyl glycerol tetraether (GDGT) lipid, as obtained e.g. from archaea of the genus Sulfolobus, optionally among other ether lipids. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine.

OIL-IN-WATER EMULSIONS FOR TOPICAL ADMINISTRATION AND USES THEREOF

Resumen de: WO2024062127A1

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS

Resumen de: WO2024061861A1

The present invention relates to a composition comprising a solid carrier, an enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the enzyme or the fragment thereof by embedding the enzyme or the fragment thereof, and a functional constituent immobilized on the surface of the protective layer. The present invention also relates to a method for the prevention, delay of progression or treatment of lung cancer in a subject using said composition and methods of producing said composition.

ANTIVIRAL SIRNA THERAPEUTIC FOR SARS-COV-2

Resumen de: AU2023347083A1

This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.

一种基于吡啶基卟啉的聚乙二醇化的纳米颗粒及其制备方法与应用

Resumen de: CN120381439A

本发明涉及一种基于吡啶基卟啉的聚乙二醇化的纳米颗粒及其制备方法与应用。本发明的纳米颗粒为壳核结构的球形纳米颗粒；所述壳为脂质‑聚乙二醇双层结构；所述核为基于吡啶基卟啉的铂离子型化合物；所述基于吡啶基卟啉的铂离子型化合物通过吡啶醇类配体与PtCl2(PhCN)2混合制备得到。本发明通过将铂类药物与质子化卟啉通过离子对结合解决了传统铂类药物的诸多问题，主要包括提高了铂类药物的水溶性以及对肿瘤细胞的细胞毒性作用，实现了化学疗法和PDT疗法的协同抗癌作用。材料无需复杂的制备过程，操作简便，易于封装。

环状RNA组合物

Resumen de: AU2023375897A1

Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.

脂质纳米颗粒冻干方法和组合物

Resumen de: AU2023393613A1

The invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent, as well as a method of preparing same.

递送治疗剂的方法和脂质组合物

Resumen de: WO2024135604A1

The object of the present invention is to provide a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells which can realize excellent delivery efficiency to organs other than the liver, and a composition containing a therapeutic agent and lipid nanoparticles which can realize excellent delivery efficiency to an organ other than the liver. The present invention provides a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells, which comprises administering a lipid composition to a subject, wherein the lipid composition comprises the therapeutic agent and lipid nanoparticle, and wherein the lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1) or a salt thereof. (1) wherein G1 represents -C(O)-, -OC(O)-, -O(CO)O- or -C(O)O-, LY represents a single bond, an alkylene group having 1-14 carbon atoms, a substituted alkylene group having 1-14 carbon atoms, a heteroalkylene group having 1-14 carbon atoms, and a substituted heteroalkylene group having 1-14 carbon atoms. X represents a basic functional group.

一种工程化强效树突状细胞疫苗及其制备方法与应用

Nº publicación: CN120381516A 29/07/2025

Solicitante:

青岛大学附属医院

Resumen de: CN120381516A

本发明公开了一种工程化强效树突状细胞疫苗及其制备方法与应用，利用纳米级抗原递送的方式，将肿瘤抗原与阳离子脂质体相融合，借助阳离子脂质电荷相互作用破坏溶酶体膜的稳定性，使部分抗原逃逸到细胞质中通过MHC I途径交叉呈递，给予DC以激活细胞免疫应答的能力对抗肿瘤；另一方面，通过合成免疫学的方法赋予DC以T细胞导向性，首先在DC表面修饰叠氮基团N3，在T细胞特异性抗体上修饰二苯并环辛炔基团DBCO，通过N3与DBCO的环加成反应将T细胞特异性抗体偶联到成熟DC表面，增加DC和T细胞接触的机会和持续时间，促进DC‑T细胞的相互作用和信号传递；两种机制的联合可克服现有DC疫苗反应率低的问题，实现抗肿瘤免疫响应的最大化。